Literature DB >> 32812881

Comment on "IL1-RN variable number of tandem repeats polymorphism with osteoarthritis risk".

Beuy Joob1, Viroj Wiwanitkit2.   

Abstract

Entities:  

Mesh:

Year:  2020        PMID: 32812881      PMCID: PMC7444869          DOI: 10.5152/j.aott.2020.19191

Source DB:  PubMed          Journal:  Acta Orthop Traumatol Turc        ISSN: 1017-995X            Impact factor:   1.511


× No keyword cloud information.
  6 in total

1.  Interleukin-6 -174G/C polymorphism and end-stage renal disease: Is there any role?

Authors:  Won Srriwijitalai; Viroj Wiwanitkit
Journal:  Saudi J Kidney Dis Transpl       Date:  2018 May-Jun

2.  Association of CCL2 Gene Variants with Osteoarthritis.

Authors:  Zhonghua Xu; Jin Li; Haoyu Yang; Lifeng Jiang; Xindie Zhou; Yong Huang; Nanwei Xu
Journal:  Arch Med Res       Date:  2019-07-24       Impact factor: 2.235

Review 3.  Association of IL-17A-197G/A and IL-17F-7488T/C polymorphisms and osteoarthritis susceptibility: A meta-analysis.

Authors:  Shutao Gao; Chao Mao; Jie Cheng; Qiang Deng; Weibin Sheng
Journal:  Int J Rheum Dis       Date:  2019-10-31       Impact factor: 2.454

4.  The genetic relationship of SOX9 polymorphisms with osteoarthritis risk in Chinese population: A case-control study.

Authors:  Yongcheng Wang; Xinyu Zhang; Xiaobo Niu; Yongsheng Xu; Long Lu; Hua Li
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.889

5.  CDH2 gene rs11564299 polymorphism is a risk factor for knee osteoarthritis in a Chinese population: a case-control study.

Authors:  Houlai Shang; Yuedong Hao; Wenhao Hu; Xiaohui Hu; Qing Jin
Journal:  J Orthop Surg Res       Date:  2019-07-09       Impact factor: 2.359

Review 6.  Meta-analysis of the association of IL1-RN variable number of tandem repeats polymorphism with osteoarthritis risk.

Authors:  Bo Xu; Xiao-Qing Shi; Run-Lin Xing; Yan-Cheng Xiao; Peng Wu; Pei-Min Wang
Journal:  Acta Orthop Traumatol Turc       Date:  2019-08-21       Impact factor: 1.511

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.